(Q30887496)

27 June 2017

1 reference

title

Mood effects of antiepileptic drugs (English)

1 reference

27 June 2017

Rianne Reijs

1

1 reference

27 June 2017

Albert P Aldenkamp

series ordinal

2

1 reference

27 June 2017

Marc De Krom

series ordinal

3

1 reference

27 June 2017

publication date

1 February 2004

1 reference

27 June 2017

1 reference

27 June 2017

volume

5 Suppl 1

1 reference

27 June 2017

page(s)

S66-76

1 reference

Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Collaborative Group for Epidemiology of Epilepsy

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Newer antiepileptic drugs and cognitive issues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Anticonvulsants: aspects of their mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Mood disorders in patients with epilepsy: epidemiology and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Cognitive and behavioural assessment in clinical trials: when should they be done?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Antiepileptic drug mechanisms of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Psychotropic effect of antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Psychopharmacological aspects of antiepileptic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Schizophrenia-like psychosis associated with anticonvulsant toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Acute effects of diphenylhydantoin in relation to plasma levels: Behavioural and psychophysiological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Rate of elimination of tracer doses of phenytoin at different steady-state serum phenytoin concentrations in epileptic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Effects of diphenylhydantoin on disruptive behavior. Study of male delinquents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Are Antidepressants Better Than Placebo?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Antiepileptic and psychotropic effect of carbamazepine (Tegretol) in the treatment of psychomotor epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A comparison of the effectiveness of primidone versus carbamazepine in epileptic outpatients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Psychotropic effects of carbamazepine in epilepsy: A double-blind comparison with phenytoin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Carbamazepine as an anticonvulsant in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Anticonvulsant drugs, cognitive function, and behavior.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Neuropsychological effects of carbamazepine and phenytoin: a reanalysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Carbamazepine offers no psychotropic advantage over phenytoin in adult epileptic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Acute psychosis with carbamazepine and sodium valproate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Behavioural effects of the new anticonvulsants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Psychometric study of children with learning problems and 14-6 positive spike EEG patterns, treated with ethosuximide (Zarontin) and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Differential regulation of gamma-aminobutyric acid receptor channels by diazepam and phenobarbital

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A characteristic form of overactive behaviour in brain damaged children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Side effects of phenobarbital in toddlers; behavioral and cognitive aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Behavioral and cognitive impairments in children with epilepsy: the long-term effects of anticonvulsant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Children of school age: the influence of antiepileptic drugs on behavior and intellect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Improvement in cognitive functioning and mood state after conversion to valproate monotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Has sodium valproate hypnotic effects?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Valproate Sodium: Evaluation of So-called Psychotropic Effect. A Controlled Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

The new antiepileptic drugs: a systematic review of their efficacy and tolerability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Effect of gabapentin (Neurontin) [corrected] on mood and well-being in patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Effects of gabapentin on cognition and quality of life in patients with epilepsy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Cognitive abilities and adjustment with gabapentin: results of a multisite study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A beneficial effect on mood in partial epilepsy patients treated with gabapentin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Treatment of social phobia with gabapentin: a placebo-controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Tiagabine: The Safety Landscape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Neuropsychological effects of tiagabine, a potential new antiepileptic drug.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Randomized double-blind parallel-group study comparing cognitive effects of a low-dose lamotrigine with valproate and placebo in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Outcomes of add-on treatment with lamotrigine in partial epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A Double-Blind, Placebo-Controlled, Prophylaxis Study of Lamotrigine in Rapid-Cycling Bipolar Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A survey comparing lamotrigine and vigabatrin in everyday clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Lamotrigine Monotherapy Improves Depressive Symptoms in Epilepsy: A Double-Blind Comparison with Valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Clinical studies on the use of lamotrigine in bipolar disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Postmarketing experience with topiramate and cognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Safety of topiramate: adverse events and relationships to dosing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

An audit of topiramate use in a general neurology clinic.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Zonisamide (CI-912) and cognition: results from preliminary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Zonisamide in epilepsy: a pilot study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

The place of anticonvulsant therapy in bipolar illness

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

The emerging role of valproate in bipolar disorder and other psychiatric disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2003.11.009

10.1016/J.YEBEH.2003.11.009

7 January 2021

Identifiers

DOI

1 reference

27 June 2017

1 reference